242 related articles for article (PubMed ID: 36602598)
1. Intensive lipid-lowering therapy for early achievement of guideline-recommended LDL-cholesterol levels in patients with ST-elevation myocardial infarction ("Jena auf Ziel").
Makhmudova U; Samadifar B; Maloku A; Haxhikadrija P; Geiling JA; Römer R; Lauer B; Möbius-Winkler S; Otto S; Schulze PC; Weingärtner O
Clin Res Cardiol; 2023 Sep; 112(9):1212-1219. PubMed ID: 36602598
[TBL] [Abstract][Full Text] [Related]
2. ESC/EAS guidelines for the detection, prevention, and treatment of individuals at risk of a first myocardial infarction: effect of 5 years of updates and the new SCORE2.
Sulman D; Zeitouni M; Silvain J; Kerneis M; Guedeney P; Barthélémy O; Brugier D; Sabouret P; Lattuca B; Mertens E; Posson J; Procopi N; Salloum T; Collet JP; Montalescot G
Eur Heart J Cardiovasc Pharmacother; 2022 Sep; 8(6):633-643. PubMed ID: 35381063
[TBL] [Abstract][Full Text] [Related]
3. Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: A randomized clinical trial.
Rubino J; MacDougall DE; Sterling LR; Hanselman JC; Nicholls SJ
Atherosclerosis; 2021 Mar; 320():122-128. PubMed ID: 33514449
[TBL] [Abstract][Full Text] [Related]
4. Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial.
Hagiwara N; Kawada-Watanabe E; Koyanagi R; Arashi H; Yamaguchi J; Nakao K; Tobaru T; Tanaka H; Oka T; Endoh Y; Saito K; Uchida T; Matsui K; Ogawa H
Eur Heart J; 2017 Aug; 38(29):2264-2276. PubMed ID: 28430910
[TBL] [Abstract][Full Text] [Related]
5. Simulation study on LDL cholesterol target attainment, treatment costs, and ASCVD events with bempedoic acid in patients at high and very-high cardiovascular risk.
Katzmann JL; Becker C; Bilitou A; Laufs U
PLoS One; 2022; 17(10):e0276898. PubMed ID: 36301892
[TBL] [Abstract][Full Text] [Related]
6. Application of the 2019 ESC/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study.
Allahyari A; Jernberg T; Hagström E; Leosdottir M; Lundman P; Ueda P
Eur Heart J; 2020 Oct; 41(40):3900-3909. PubMed ID: 32072178
[TBL] [Abstract][Full Text] [Related]
7. Patients With High Cardiovascular Risk as Candidates to Bempedoic Acid, After Treatment With Statins, Ezetimibe and PCSK9 Inhibitors: An Estimation and Cost-Effectiveness Analysis.
Seijas-Amigo J; Cordero A; Olmo RF; Cortez Quiroga GA; Fácila L; Salgado-Barreira Á; Reyes-Santías F; Romero-Menor C; Murillo JR; Rodríguez-Mañero M; Bello Mora MC; Valle A; Sandin M; Pamias RF; Bañeras J; García PB; Lorenzo MC; Sánchez-Alvarez S; López-Rodríguez L; González-Juanatey JR
J Cardiovasc Pharmacol; 2023 Jan; 81(1):70-75. PubMed ID: 36219195
[TBL] [Abstract][Full Text] [Related]
8. The prevalence of hyperlipidemia and features of lipid-lowering therapy in patients with myocardial infarction according to the Russian register of acute myocardial infarction REGION-MI.
Boytsov SA; Shakhnovich RM; Tereschenko SN; Erlikh AD; Kukava NG; Pevsner DV; Rytova YK
Kardiologiia; 2022 Jul; 62(7):12-22. PubMed ID: 35989625
[TBL] [Abstract][Full Text] [Related]
9. Available oral lipid-lowering agents could bring most high-risk patients to target: an estimate based on the Dyslipidemia International Study II-Italy.
De Ferrari GM; Perna GP; Nicosia A; Guasti L; Casu G; Cuccia C; Picco F; Strazzella C; Totaro R; Cercone S; Canullo L; Horack M; Lautsch D; Gitt AK; Di Biase M
J Cardiovasc Med (Hagerstown); 2018 Sep; 19(9):485-490. PubMed ID: 29917002
[TBL] [Abstract][Full Text] [Related]
10. PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations.
Hao Q; Aertgeerts B; Guyatt G; Bekkering GE; Vandvik PO; Khan SU; Rodondi N; Jackson R; Reny JL; Al Ansary L; Van Driel M; Assendelft WJJ; Agoritsas T; Spencer F; Siemieniuk RAC; Lytvyn L; Heen AF; Zhao Q; Riaz IB; Ramaekers D; Okwen PM; Zhu Y; Dawson A; Ovidiu MC; Vanbrabant W; Li S; Delvaux N
BMJ; 2022 May; 377():e069066. PubMed ID: 35508320
[TBL] [Abstract][Full Text] [Related]
11. PCSK9 inhibitor, ezetimibe, and bempedoic acid: Evidence-based therapies for statin-intolerant patients.
Gunta SP; O'Keefe JH; O'Keefe EL; Lavie CJ
Prog Cardiovasc Dis; 2023; 79():12-18. PubMed ID: 36871887
[TBL] [Abstract][Full Text] [Related]
12. LDL cholesterol target achievement in heterozygous familial hypercholesterolemia patients according to 2019 ESC/EAS lipid guidelines: Implications for newer lipid-lowering treatments.
Rizos CV; Skoumas I; Rallidis L; Skalidis E; Tziomalos K; Garoufi A; Anagnostis P; Sfikas G; Kotsis V; Doumas M; Kolovou G; Lambadiari V; Dima I; Kiouri E; Zacharis E; Agapakis D; Attilakos A; Antza C; Vlachopoulos C; Liberopoulos EN
Int J Cardiol; 2021 Dec; 345():119-124. PubMed ID: 34687802
[TBL] [Abstract][Full Text] [Related]
13. Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy.
Foody JM; Toth PP; Tomassini JE; Sajjan S; Ramey DR; Neff D; Tershakovec AM; Hu H; Tunceli K
Vasc Health Risk Manag; 2013; 9():719-27. PubMed ID: 24265554
[TBL] [Abstract][Full Text] [Related]
14. Lipid-lowering treatment up to one year after acute coronary syndrome: guidance from a French expert panel for the implementation of guidelines in practice.
Sabouret P; Puymirat E; Kownator S; Abdennbi K; Lebeau F; Meltz M; Angoulvant D; Schiele F
Panminerva Med; 2023 Jun; 65(2):244-249. PubMed ID: 36222543
[TBL] [Abstract][Full Text] [Related]
15. An estimation of the consequences of reinforcing the 2016 and 2019 European Society of Cardiology/European Atherosclerosis Society guidelines on current lipid-lowering treatment in patients with type 2 diabetes in tertiary care-a SwissDiab study.
Singeisen H; Renström F; Laimer M; Lehmann R; Bilz S; Brändle M
Eur J Prev Cardiol; 2023 Oct; 30(14):1473-1481. PubMed ID: 37226890
[TBL] [Abstract][Full Text] [Related]
16. Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) Trial.
Nissen SE; Dent-Acosta RE; Rosenson RS; Stroes E; Sattar N; Preiss D; Mancini GB; Ballantyne CM; Catapano A; Gouni-Berthold I; Stein EA; Xue A; Wasserman SM; Scott R; Thompson PD;
Clin Cardiol; 2016 Mar; 39(3):137-44. PubMed ID: 26946077
[TBL] [Abstract][Full Text] [Related]
17. The impact of the 2019 ESC/EAS dyslipidaemia guidelines on real-world initial lipid-lowering therapy in patients with acute myocardial infarction.
Kong X; He G; Quan X; Tan Z; Yan F; Chen X
Medicine (Baltimore); 2024 Mar; 103(12):e37637. PubMed ID: 38517999
[TBL] [Abstract][Full Text] [Related]
18. Effect of Ezetimibe + Pitavastatin on Cardiovascular Outcomes in Patients with ST-Segment Elevation Myocardial Infarction (from the HIJ-PROPER Study).
Otsuki H; Arashi H; Yamaguchi J; Kawada-Watanabe E; Ogawa H; Hagiwara N
Am J Cardiol; 2020 Oct; 132():15-21. PubMed ID: 32773226
[TBL] [Abstract][Full Text] [Related]
19. Lipid Lowering Treatment and Eligibility for PCSK9 Inhibition in Post-Myocardial Infarction Patients in Italy: Insights from Two Contemporary Nationwide Registries.
Colivicchi F; Massimo Gulizia M; Arca M; Luigi Temporelli P; Gonzini L; Venturelli V; Morici N; Indolfi C; Gabrielli D; De Luca L
Cardiovasc Ther; 2020; 2020():3856242. PubMed ID: 31969932
[TBL] [Abstract][Full Text] [Related]
20. How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic.
Barkas F; Milionis H; Kostapanos MS; Mikhailidis DP; Elisaf M; Liberopoulos E
Curr Med Res Opin; 2015 Feb; 31(2):221-8. PubMed ID: 25418708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]